FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
• The FDA is currently reviewing Moderna's mRNA-based flu vaccine, which would be the first of its kind to enter the commercial market. • This decision comes amid a climate of skepticism regarding mRNA technology, highlighted by questions from RFK Jr. and recent HHS funding cuts. • The regulatory uncertainty and funding drops have alarmed venture capital firms, threatening the development of mRNA therapies for Lyme disease and rare cancers.
npr.org
